<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IRINOTECAN HYDROCHLORIDE- irinotecan hydrochlorideÂ injectionÂ </strong><br>Cipla Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Irinotecan safely and effectively. See full prescribing information for Irinotecan. <br><br>Irinotecan  Injection, intravenous infusion Initial U.S. Approval: 1996 <br>
</div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> </span></h1>
<h1 class="Warning"><span class="Bold">â€¢ Early and late forms of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can occur. Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can be life threatening and should be treated promptly with loperamide. Monitor patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Interrupt Irinotecan and reduce subsequent doses if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs </span></h1>
<p class="Highlighta"><span class="Bold">â€¢ Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may occur</span> </p>
</div>
<div></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> </span></h1>
<h1 class="Warning"><span class="Bold">â€¢ Early and late forms of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can occur. Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can be life threatening and should be treated promptly with loperamide. Monitor patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Interrupt Irinotecan and reduce subsequent doses if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs </span></h1>
<p class="Highlighta"><span class="Bold">â€¢ Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may occur</span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Irinotecan is a topoisomerase inhibitor indicated for:  </p>
<p class="Highlighta">First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum (<a href="#ID746">1</a>)  </p>
<p class="Highlighta">Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy (<a href="#ID746">1</a>)  </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li> Colorectal cancer combination regimen 1: Irinotecan 125 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m<span class="Sup">2</span> intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks (<a href="#ID753">2.1</a>) </li>
<li> Colorectal cancer combination regimen 2: Irinotecan 180 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m<span class="Sup">2</span> intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 20 followed by 5-FU 400 mg/m<span class="Sup">2</span> intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m<span class="Sup">2</span> intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30. (<a href="#ID753">2.1</a>) </li>
<li> Colorectal cancer single agent regimen 1: Irinotecan 125 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (<a href="#ID758">2.2</a>) </li>
<li> Colorectal cancer single agent regimen 2: Irinotecan 350 mg/m<span class="Sup">2</span> intravenous infusion over 90 minutes on day 1 every 3 weeks. (<a href="#ID758">2.2</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Irinotecan hydrochloride Injection is available in three single-dose sizes:   (<a href="#section-3">3</a>)</p>
<ul class="Disc">
<li>2 mL-fill vial containing 40 mg Irinotecan hydrochloride injection </li>
<li>5 mL-fill vial containing 100 mg Irinotecan hydrochloride injection</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Irinotecan or its excipients (<a href="#ID778">4</a>) </li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Â  <span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span>Â <span class="Bold">and</span>Â <span class="Bold">cholinergic</span>Â <span class="Bold">reactions:</span>  Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occurring during or shortly after infusion of Irinotecan) is usually transient and may be accompanied by cholinergic symptoms. Consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated). Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (generally occurring more than 24 hours after administration of Irinotecan) can occur. Monitor and replace fluid and electrolytes. Treat with loperamide. Use antibiotic support for <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Interrupt Irinotecan and reduce subsequent doses if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#ID785">5.1</a>) </li>
<li>Â  <span class="Bold"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>:</span>  Manage promptly with antibiotic support. Interrupt Irinotecan and reduce subsequent doses if necessary. (<a href="#ID787">5.2</a>) </li>
<li>Â  <span class="Bold">Patients</span>Â <span class="Bold">with</span>Â <span class="Bold">Reduced</span>Â <span class="Bold">UGT1A1</span>Â <span class="Bold">Activity:</span>  Individuals who are homozygous for the UGT1A1<span class="Sup">*</span>28 allele are at increased risk for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> following initiation of Irinotecan treatment. (<a href="#ID789">5.3</a>) </li>
<li>Â  <span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span>  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including severe anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been observed. Discontinue Irinotecan if this occurs. (<a href="#ID791">5.4</a>) </li>
<li>Â  <span class="Bold">Renal</span>Â <span class="Bold">Impairment/Renal</span>Â <span class="Bold">Failure:</span>  Rare cases of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been identified, usually in patients who became volume depleted from severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (<a href="#ID793">5.5</a>) </li>
<li>Â  <span class="Bold">Pulmonary</span>Â <span class="Bold">Toxicity:</span>  Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred. Interrupt for new or progressive dysnpnea, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> pending evaluation. If IPD diagnosed, discontinue and institute appropriate treatment as needed. (<a href="#ID795">5.6</a>) </li>
<li>Â  <span class="Bold">Toxicity</span>Â <span class="Bold">of</span>Â <span class="Bold">the</span>Â <span class="Bold">5</span>Â <span class="Bold">Day</span>Â <span class="Bold">Regimen:</span>  Irinotecan should not be used in combination with a regimen of 5-FU/LV administered for 4-5 consecutive days every 4 weeks outside of a clinical study. (<a href="#ID797">5.7</a>) </li>
<li>Â  <span class="Bold">Pregnancy:</span>  Irinotecan can cause fetal harm when administered to a pregnant woman. (<a href="#ID801">5.9</a>) </li>
<li>Â  <span class="Bold">Hepatic</span>Â <span class="Bold">Impairment:</span>  In clinical trials, Irinotecan has not been administered to patients with serum bilirubin &gt; 2.0 mg/dL, or transaminases &gt; 3 times ULN if no liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, or transaminases &gt; 5 times ULN if liver <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. With the weekly dosage schedule, patients with total bilirubin levels 1.0-2.0 mg/dL had greater likelihood of grade 3-4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. (<a href="#ID803">5.10</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions (<span class="Underline">&gt;</span>30%) observed in combination therapy clinical studies are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, abnormal bilirubin, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. (<a href="#ID808">6.1</a>)  </p>
<p class="Highlighta">Common adverse reactions (<span class="Underline">&gt;</span>30%) observed in single agent therapy clinical studies are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, body weight decreasing, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. (<a href="#ID808">6.1</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Cipla Limited, at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">â—? Strong CYP3A4 Inducers: Do not administer for at least 2 weeks prior to initiation of Irinotecan therapy (<a href="#ID829">7.2</a>)  </p>
<p class="Highlighta">â—? Strong CYP3A4 Inhibitors: Discontinue at least 1 week prior to starting Irinotecan therapy and do not use during Irinotecan therapy (<a href="#ID831">7.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"> â—? <span class="Bold">Nursing</span>Â <span class="Bold">Mothers:</span> Discontinue nursing when receiving therapy with Irinotecan (<a href="#ID844">8.3</a>)  </p>
<p class="Highlighta"> â—? <span class="Bold">Geriatric</span>Â <span class="Bold">Use:</span> Closely monitor patients greater than 65 years of age because of a greater risk of early and late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in this population (<a href="#ID846">8.5</a>)  </p>
<p class="Highlighta"> â—? <span class="Bold">Patients</span>Â <span class="Bold">with</span>Â <span class="Bold">Renal</span>Â <span class="Bold">Impairment</span>: Use caution and do not use in patients on dialysis (<a href="#ID848">8.6</a>)  </p>
<p class="Highlighta"> â—? <span class="Bold">Patients</span>Â <span class="Bold">with</span>Â <span class="Bold">Hepatic</span>Â <span class="Bold">Impairment</span>: Use caution (<a href="#ID753">2.1</a>, <a href="#ID803">5.10</a>, <a href="#ID850">8.7</a>, <a href="#ID862">12.3</a>)  </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Colorectal Cancer Combination Regimens 1 and 2</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Colorectal Single Agent Regimens 1 and 2</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage in Patients with Reduced UGT1A1 Activity</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Premedication</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Preparation of Infusion Solution</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Safe Handling</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and Cholinergic Reactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Patients With Reduced UGT1A1 Activity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>/<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Toxicity of the 5 Day Regimen</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Increased Toxicity in Patients with Performance Status 2</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Pregnancy</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 5-Fluorouracil (5-FU) and Leucovorin (LV)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Strong CYP 3A4 Inducers</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Strong CYP 3A4 Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Atazanavir Sulfate</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Drug-Laboratory Test Interactions</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10. OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12. CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13. NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14. CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Metastatic Colorectal Cancer</a></h2>
<h1><a href="#section-14" class="toc">15. REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID741"></a><a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID906"></a><a name="section-1.1"></a><p></p>
<p class="First"><a name="ID907"></a><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span> AND <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span> </span></p>
<p><span class="Bold"> â€¢ Early and late forms of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can occur. Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can be life threatening and should be treated promptly with loperamide. Monitor patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Interrupt Irinotecan and reduce subsequent doses if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs</span></p>
<p><span class="Bold"> â€¢ Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> may occur</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID746"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID893"></a><a name="section-1.1"></a><p></p>
<ul class="Disc">
<li>Â  Irinotecan hydrochloride Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. </li>
<li>Â  Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID750"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="ID753"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Colorectal Cancer Combination Regimens 1 and 2</h2>
<p class="First"><a name="ID754"></a>Administer Irinotecan as a 90-minute intravenous infusion followed by LV and 5-FU. The currently recommended regimens are shown in Table 1. </p>
<p>A reduction in the starting dose by one dose level of Irinotecan may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.</p>
<div class="Figure"><img alt="Image 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-01.jpg"></div>
<p><a name="ID756"></a>Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients <span class="Italics">[see</span>Â <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID803">5.10</a>)</span>, <span class="Italics">Use</span>Â <span class="Italics">in</span>Â <span class="Italics">Specific</span>Â <span class="Italics">Populations</span>Â <span class="Italics">(<a href="#ID850">8.7</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)]</span>.</p>
<p><span class="Underline">Dose Modifications </span>Based on recommended dose levels described in Table 1, Combination Regimens of Irinotecan and Dose Modifications, subsequent doses should be adjusted as suggested in Table 2, Recommended Dose Modifications for Combination Regimens. All dose modifications should be based on the worst preceding toxicity.</p>
<div class="Figure"><img alt="Image 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-02.jpg"></div>
</div>
<div class="Section">
<a name="ID758"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Colorectal Single Agent Regimens 1 and 2</h2>
<p class="First"><a name="ID759"></a>Administer Irinotecan as a 90-minute intravenous infusion. The currently recommended regimens are shown in Table 3.</p>
<p>Â Â Â Â Â Â Â Â Â Â Â  </p>
<p>A reduction in the starting dose by one dose level of Irinotecan may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels. Dosing for patients with bilirubin &gt;2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.</p>
<div class="Figure"><img alt="Image 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-03.jpg"></div>
<p><a name="ID761"></a><span class="Underline">Dose Modifications </span></p>
<p>Based on recommended dose-levels described in Table 3, Single-Agent Regimens of Irinotecan and Dose Modifications, subsequent doses should be adjusted as suggested in Table 4, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.</p>
<div class="Figure"><img alt="Image 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-04.jpg"></div>
</div>
<div class="Section">
<a name="ID763"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage in Patients with Reduced UGT1A1 Activity</h2>
<p class="First"><a name="ID764"></a>When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of Irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele [see Dosage and Administration (<a href="#ID753">2.1</a> and <a href="#ID758">2.2</a>) and Warnings and Precautions (<a href="#ID789">5.3</a>)]. However, the precise dose reduction in this patient population is not known, and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 1-4).</p>
</div>
<div class="Section">
<a name="ID765"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Premedication</h2>
<p class="First"><a name="ID766"></a>It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as a 5-HT<span class="Sup">3</span> blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of Irinotecan. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. A similar antiemetic regimen should be used with Irinotecan in combination therapy. </p>
<p><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms.</p>
</div>
<div class="Section">
<a name="ID767"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Preparation of Infusion Solution</h2>
<p class="First"><a name="ID768"></a>Inspect vial contents for particulate matter and discoloration and repeat inspection when drug product is withdrawn from vial into syringe. </p>
<p>Irinotecan hydrochloride Injection 20 mg/mL is intended for single use only and any unused portion should be discarded. </p>
<p>Irinotecan hydrochloride Injection must be diluted prior to infusion. Irinotecan should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution. </p>
<p>The solution is physically and chemically stable for up to 24 hours at room temperature and in ambient fluorescent lighting. Solutions diluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately 2Â° to 8Â°C, 36Â° to 46Â°F), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Chloride Injection, USP, is not recommended due to a low and sporadic incidence of visible particulates. Freezing Irinotecan and admixtures of Irinotecan may result in precipitation of the drug and should be avoided. </p>
<p>The Irinotecan hydrochloride Injection solution should be used immediately after reconstitution as it contains no antibacterial preservative. Because of possible microbial contamination during dilution, it is advisable to use the admixture prepared with 5% Dextrose Injection, USP, within 24 hours if refrigerated (2Â° to 8Â°C, 36Â° to 46Â°F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within 4 hours if kept at room temperature. If reconstitution and dilution are performed under strict aseptic conditions (e.g. on Laminar Air Flow bench), Irinotecan hydrochloride Injection solution should be used (infusion completed) within 12 hours at room temperature or 24 hours if refrigerated (2Â° to 8Â°C, 36Â° to 46Â°F).</p>
</div>
<div class="Section">
<a name="ID769"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Safe Handling</h2>
<p class="First"><a name="ID770"></a>Care should be exercised in the handling and preparation of infusion solutions prepared from Irinotecan hydrochloride Injection. The use of gloves is recommended. If a solution of Irinotecan contacts the skin, wash the skin immediately and thoroughly with soap and water. If Irinotecan contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available.</p>
</div>
<div class="Section">
<a name="ID771"></a><a name="section-2.7"></a><p></p>
<h2>2.7 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></h2>
<p class="First"><a name="ID772"></a>Care should be taken to avoid <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>, and the infusion site should be monitored for signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Should <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occur, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> the site with sterile water and applications of ice are recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID773"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID908"></a><a name="section-3.1"></a><p></p>
<p class="First"><a name="ID774"></a>Irinotecan hydrochloride Injection is available in two single-dose sizes: </p>
<p>Â Â Â  â—? 2 mL-fill vial containing 40 mg Irinotecan hydrochloride </p>
<p>Â Â Â  â—? 5 mL-fill vial containing 100 mg Irinotecan hydrochloride </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID778"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID909"></a><a name="section-4.1"></a><p></p>
<p class="First"><a name="ID779"></a>â—? Irinotecan hydrochloride Injection is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its excipients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID782"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="ID785"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and Cholinergic Reactions</h2>
<p class="First"><a name="ID786"></a>Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (occurring during or shortly after infusion of Irinotecan) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and intestinal hyperperistalsis that can cause abdominal cramping. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> may also occur. Early <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and other cholinergic symptoms may be prevented or treated. Consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated). These symptoms are expected to occur more frequently with higher Irinotecan doses. </p>
<p>Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (generally occurring more than 24 hours after administration of Irinotecan) can be life threatening since it may be prolonged and may lead to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Grade 3-4 late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 23-31% of patients receiving weekly dosing. In the clinical studies, the median time to the onset of late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 5 days with 3-week dosing and 11 days with weekly dosing. Late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can be complicated by <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, obstruction, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Cases of <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> have been reported. Patients should have loperamide readily available to begin treatment for late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Begin loperamide at the first episode of poorly formed or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is 4 mg at the first onset of late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and then 2 mg every 2 hours until the patient is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. During the night, the patient may take 4 mg of loperamide every 4 hours. Monitor and replace fluid and electrolytes. Use antibiotic support for <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Subsequent weekly chemotherapy treatments should be delayed in patients until return of pretreatment bowel function for at least 24 hours without anti-<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> medication. Patients must not be treated with Irinotecan until resolution of the <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>. If grade 2, 3, or 4 late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> recurs, subsequent doses of Irinotecan should be decreased <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p>Avoid diuretics or laxatives in patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section">
<a name="ID787"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First"><a name="ID788"></a><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> following severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported in patients treated with Irinotecan. In the clinical studies evaluating the weekly dosage schedule, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span> (concurrent NCI grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> of grade 2 or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Manage <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> promptly with antibiotic support <span class="Italics">[see</span>Â <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID787">5.2</a>)]</span>. Hold Irinotecan if <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span> occurs or if the absolute neutrophil count drops &lt;1000/mm<span class="Sup">3</span>. After recovery to an absolute neutrophil count â‰¥1000/mm<span class="Sup">3</span>, subsequent doses of Irinotecan should be reduced <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p>When evaluated in the trials of weekly administration, the frequency of grade 3 and 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation (48% [13/27] versus 24% [67/277]; p=0.04). Patients who have previously received pelvic/abdominal irradiation are at increased risk of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> following the administration of Irinotecan. Based on sparse available data, the concurrent administration of Irinotecan with irradiation is not recommended. </p>
<p>Patients with baseline serum total bilirubin levels of 1.0 mg/dL or more also had a greater likelihood of experiencing first-cycle grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/266]; p&lt;0.001). Patients with deficient glucuronidation of bilirubin, such as those with Gilbert's syndrome, may be at greater risk of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> when receiving therapy with Irinotecan.</p>
</div>
<div class="Section">
<a name="ID789"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Patients With Reduced UGT1A1 Activity</h2>
<p class="First"><a name="ID790"></a>Individuals who are homozygous for the UGT1A1<span class="Sup">*</span>28 allele (UGT1A1 7/7 genotype) are at increased risk for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> following initiation of Irinotecan treatment. </p>
<p>In a study of 66 patients who received single-agent Irinotecan (350 mg/m<span class="Sup">2</span> once-every3-weeks), the incidence of grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients homozygous for the UGT1A1<span class="Sup">*</span>28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%. No grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype). </p>
<p>In a prospective study (n=250) to investigate the role of UGT1A1<span class="Sup">*</span>28 polymorphism in the development of toxicity in patients treated with Irinotecan (180 mg/m<span class="Sup">2</span>) in combination with infusional 5-FU/LV, the incidence of grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients homozygous for the UGT1A1<span class="Sup">*</span>28 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%. Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was observed in 1.8% of patients homozygous for the wild-type allele. </p>
<p>In another study in which 109 patients were treated with Irinotecan (100-125 mg/m<span class="Sup">2</span>) in combination with bolus 5-FU/LV, the incidence of grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in patients homozygous for the UGT1A1<span class="Sup">*</span>28 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%. Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was observed in 6.8% of patients homozygous for the wild-type allele. </p>
<p>When administered in combination with other agents or as a single-agent, a reduction in the starting dose by at least one level of Irinotecan should be considered for patients known to be homozygous for the UGT1A1<span class="Sup">*</span>28 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p><span class="Underline">UGT1A1 Testing </span></p>
<p>A laboratory test is available to determine the UGT1A1 status of patients. Testing can detect the UGT1A1 6/6, 6/7 and 7/7 genotypes.</p>
</div>
<div class="Section">
<a name="ID791"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><a name="ID792"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including severe anaphylactic or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been observed. Discontinue Irinotecan if <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs.</p>
</div>
<div class="Section">
<a name="ID793"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>/<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First"><a name="ID794"></a><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been identified, usually in patients who became volume depleted from severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
</div>
<div class="Section">
<a name="ID795"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Pulmonary Toxicity</h2>
<p class="First"><a name="ID796"></a>Interstitial Pulmonary Disease (IPD)-like events, including fatalities, have occurred in patients receiving Irinotecan (in combination and as monotherapy). Risk factors include preexisting <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, use of pneumotoxic drugs, radiation therapy, and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during Irinotecan therapy. In Japanese studies, a reticulonodular pattern on chest x-ray was observed in a small percentage of patients. New or progressive, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> should prompt interruption of chemotherapy, pending diagnostic evaluation. If IPD is diagnosed, Irinotecan and other chemotherapy should be discontinued and appropriate treatment instituted as needed <span class="Italics">[see</span>Â <span class="Italics">Adverse</span>Â <span class="Italics">Reactions</span>Â <span class="Italics">(<a href="#ID808">6.1</a>)]</span>.</p>
</div>
<div class="Section">
<a name="ID797"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Toxicity of the 5 Day Regimen</h2>
<p class="First"><a name="ID798"></a>Outside of a well-designed clinical study, Irinotecan hydrochloride Injection should not be used in combination with a regimen of 5-FU/LV administered for 4-5 consecutive days every 4 weeks because of reports of increased toxicity, including toxic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Irinotecan should be used as recommended in Table 2 <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
</div>
<div class="Section">
<a name="ID799"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Increased Toxicity in Patients with Performance Status 2</h2>
<p class="First"><a name="ID800"></a>In patients receiving either Irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, first-cycle treatment discontinuation, and early <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed in patients with a baseline performance status of 2 than in patients with a baseline performance status of 0 or 1.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID801"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Pregnancy</h2>
<p class="First"><a name="ID802"></a>Irinotecan can cause fetal harm when administered to a pregnant woman. Irinotecan was embryotoxic in rats and rabbits at doses significantly lower than those administered to humans on a mg/m<span class="Sup">2</span> basis. In rats, at exposures approximately 0.2 times those achieved in humans at the 125 mg/m<span class="Sup">2</span> dose, Irinotecan was embryotoxic and resulted in decreased learning ability and female fetal body weight in surviving pups; the drug was teratogenic at lower exposures (approximately 0.025 times the AUC in humans at the 125 mg/m<span class="Sup">2</span> dose).There are no adequate and well-controlled studies of Irinotecan in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Irinotecan.</p>
</div>
<div class="Section">
<a name="ID803"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="ID804"></a>The use of Irinotecan in patients with significant <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been established. In clinical trials of either dosing schedule, Irinotecan was not administered to patients with serum bilirubin &gt;2.0 mg/dL, or transaminase &gt;3 times the upper limit of normal if no liver <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>, or transaminase &gt;5 times the upper limit of normal with liver <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>. In clinical trials of the weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dL) had a significantly greater likelihood of experiencing first-cycle, grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/226]; p&lt;0.001) <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID753">2.1</a>)</span>, <span class="Italics">Use</span>Â <span class="Italics">in</span>Â <span class="Italics">Specific</span>Â <span class="Italics">Populations</span>Â <span class="Italics">(<a href="#ID850">8.7</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID805"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS</h1>
<div class="Section">
<a name="ID808"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First"><a name="ID809"></a>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Common adverse reactions (<span class="Underline">&gt;</span>30%) observed in combination therapy clinical studies are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, abnormal bilirubin, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. </p>
<p>Common adverse reactions (<span class="Underline">&gt;</span>30%) observed in single agent therapy clinical studies are: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (including <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, body weight decreasing, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. </p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> have not been observed, and no complications have specifically been attributed to <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphocytopenia</span>. </p>
<p><span class="Underline">First-Line Combination Therapy </span></p>
<p>A total of 955 patients with metastatic colorectal cancer received the recommended regimens of Irinotecan in combination with 5-FU/LV, 5-FU/LV alone, or Irinotecan alone. In the two phase 3 studies, 370 patients received Irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received Irinotecan alone <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p>In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received Irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received Irinotecan alone. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> potentially related to treatment occurred in 2 (0.9%) patients who received Irinotecan in combination with 5-FU/LV (2 <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>), 3 (1.4%) patients who received 5-FU/LV alone (1 <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>/<span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, 1 CNS <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, 1 unknown) and 2 (0.9%) patients who received Irinotecan alone (2 <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received Irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received Irinotecan alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received Irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5FU/LV alone, and 26 (11.7%) patients who received Irinotecan alone. </p>
<p>In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received Irinotecan in combination with 5-FU/LV and 4 (2.8%) received 5-FU/LV alone. There was one potentially treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, which occurred in a patient who received Irinotecan in combination with 5-FU/LV (0.7%, <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span>). <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> from any cause within 60 days of first study treatment were reported for 3 (2.1%) patients who received Irinotecan in combination with 5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for 9 (6.2%) patients who received Irinotecan in combination with 5FU/LV and 1 (0.7%) patient who received 5-FU/LV alone. </p>
<p>The most clinically significant adverse events for patients receiving Irinotecan-based therapy were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. The most clinically significant adverse events for patients receiving 5-FU/LV therapy were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>. In Study 1, grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span> (defined as grade 2 <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> were observed less often with weekly Irinotecan/5-FU/LV than with monthly administration of 5-FU/LV. </p>
<p>Tables 5 and 6 list the clinically relevant adverse events reported in Studies 1 and 2, respectively.</p>
<div class="Figure"><img alt="Image 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-05.jpg"></div>
<div class="Figure"><img alt="Image 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-06.jpg"></div>
<div class="Figure"><img alt="Image 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-07.jpg"></div>
<div class="Figure"><img alt="image 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-08.jpg"></div>
<div class="Figure"><img alt="Pmage 9" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-09.jpg"></div>
<p><a name="ID815"></a><span class="Underline">Second-Line Single-Agent Therapy </span></p>
<p><span class="Bold"><span class="Italics">Weekly</span></span>Â <span class="Bold"><span class="Italics">Dosage</span></span>Â <span class="Bold"><span class="Italics">Schedule</span></span>Â </p>
<p>In three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with Irinotecan. Seventeen of the patients died within 30 days of the administration of Irinotecan; in five cases (1.6%, 5/304), the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were potentially drug-related. One of the patients died of <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span> without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Neutropenic fever</span> occurred in nine (3.0%) other patients; these patients recovered with supportive care. </p>
<p>One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of Irinotecan. The primary reasons for drug-related hospitalization were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (18.4%); <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, with or without <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and/or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (8.2%); and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4.9%). </p>
<p>The first dose of at least one cycle of Irinotecan was reduced for 67% of patients who began the studies at the 125-mg/m2 starting dose. Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m2 dose level. The most common reasons for dose reduction were late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. Thirteen (4.3%) patients discontinued treatment with Irinotecan because of adverse events. The adverse events in Table 7 are based on the experience of the 304 patients enrolled in the three studies described in CLINICAL STUDIES (<a href="#ID871">14.1</a>).</p>
<div class="Figure"><img alt="Image 10" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-10.jpg"></div>
<div class="Figure"><img alt="Image 11" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-11.jpg"></div>
<p><a name="ID818"></a><span class="Bold"><span class="Italics">Once-Every-3-Week</span></span>Â <span class="Bold"><span class="Italics">Dosage</span></span>Â <span class="Bold"><span class="Italics">Schedule</span></span>Â </p>
<p>A total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase 3 studies: 316 received Irinotecan, 129 received 5-FU, and 90 received best supportive care. Eleven (3.5%) patients treated with Irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were potentially related to Irinotecan treatment and were attributed to neutropenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, grade 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was attributed to grade 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </p>
<p>Hospitalizations due to serious adverse events occurred at least once in 60% (188/316) of patients who received Irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with Irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events. </p>
<p>Of the 316 patients treated with Irinotecan, the most clinically significant adverse events (all grades, 1-4) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (84%), <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (72%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (70%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (62%), cholinergic symptoms (47%), and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (30%). Table 8 lists the grade 3 and 4 adverse events reported in the patients enrolled to all treatment arms of the two studies described in <span class="Italics">CLINICAL</span>Â <span class="Italics">STUDIES</span>Â <span class="Italics">(<a href="#ID871">14.1</a>)</span>.</p>
<div class="Figure"><img alt="Image 12" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-12.jpg"></div>
<div class="Figure"><img alt="Image 13" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-13.jpg"></div>
<p><a name="ID821"></a>The incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as Irinotecan than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.Â  </p>
</div>
<div class="Section">
<a name="ID822"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First"><a name="ID823"></a>The following adverse reactions have been identified during post approval use of Irinotecan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<p>Myocardial ischemic events have been observed following Irinotecan therapy. <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span> have been observed in patients receiving Irinotecan. </p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, asymptomatic pancreatic enzyme elevation have been reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> have been observed. </p>
<p><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, mostly with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, has been reported.</p>
<p>Transient <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> has been reported in patients treated with Irinotecan; in some cases, the event was attributed to the <span class="product-label-link" type="condition" conceptid="440895" conceptname="Poisoning by parasympathomimetic drug">cholinergic syndrome</span> observed during or shortly after infusion of Irinotecan. </p>
<p>Interaction between Irinotecan and neuromuscular blocking agents cannot be ruled out. Irinotecan has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> of non-depolarizing drugs may be antagonized.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID824"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS</h1>
<div class="Section">
<a name="ID827"></a><a name="section-7.1"></a><p></p>
<h2>7.1 5-Fluorouracil (5-FU) and Leucovorin (LV)</h2>
<p class="First"><a name="ID828"></a>In a phase 1 clinical study involving Irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, the disposition of Irinotecan was not substantially altered when the drugs were co-administered. Although the C<span class="Sub">max</span> and AUC<span class="Sub">0-24</span> of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when Irinotecan was followed by 5FU and LV administration compared with when Irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. Formal <span class="Italics">in</span>Â <span class="Italics">vivo</span> or <span class="Italics">in</span>Â <span class="Italics">vitro</span> drug interaction studies to evaluate the influence of Irinotecan on the disposition of 5-FU and LV have not been conducted.</p>
</div>
<div class="Section">
<a name="ID829"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Strong CYP 3A4 Inducers</h2>
<p class="First"><a name="ID830"></a><span class="Underline">Anticonvulsants and other strong inducers: </span>Exposure to Irinotecan and its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine. The appropriate starting dose for patients taking these anticonvulsants or other strong inducers such as rifampin and rifabutin has not been defined. Consideration should be given to substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of Irinotecan therapy. </p>
<p><span class="Underline">St. John's wort: </span>Exposure to the active metabolite SN-38 is reduced in patients receiving concomitant St. John's wort. St. John's wort should be discontinued at least 2 weeks prior to the first cycle of Irinotecan, and St. John's wort is contraindicated during Irinotecan therapy. </p>
<p><span class="Underline">Dexamethasone</span>, a moderate CYP3A4 inducer, does not appear to alter the pharmacokinetics of Irinotecan.</p>
</div>
<div class="Section">
<a name="ID831"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Strong CYP 3A4 Inhibitors</h2>
<p class="First"><a name="ID832"></a>Ketoconazole is a strong inhibitor of CYP3A4 enzymes. Patients receiving concomitant ketoconazole have increased exposure to Irinotecan and its active metabolite SN-38. Patients should discontinue ketoconazole at least 1 week prior to starting Irinotecan therapy and ketoconazole is contraindicated during Irinotecan therapy.</p>
</div>
<div class="Section">
<a name="ID833"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Atazanavir Sulfate</h2>
<p class="First"><a name="ID834"></a>Coadministration of atazanavir sulfate, a CYP3A4 and UGT1A1 inhibitor has the potential to increase systemic exposure to SN-38, the active metabolite of Irinotecan. Physicians should take this into consideration when co-administering these drugs. </p>
</div>
<div class="Section">
<a name="ID835"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Drug-Laboratory Test Interactions</h2>
<p class="First"><a name="ID836"></a>There are no known interactions between Irinotecan and laboratory tests.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID837"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID840"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="ID841"></a>Pregnancy Category D <span class="Italics">[see</span>Â <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID801">5.9</a>)]</span>Â </p>
<p>Irinotecan can cause fetal harm when administered to a pregnant woman. Radioactivity related to <span class="Sup">14</span>C-Irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an Irinotecan C<span class="Sub">max</span> and AUC about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>). Intravenous administration of Irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. In separate studies in rats, this dose produced an Irinotecan C<span class="Sub">max</span> and AUC of about 2 and 0.2 times, respectively, the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>. In rabbits, the embryotoxic dose was about one-half the recommended human weekly starting dose on a mg/m<span class="Sup">2</span> basis. Irinotecan was teratogenic in rats at doses greater than 1.2 mg/kg/day and in rabbits at 6.0 mg/kg/day. In separate studies in rats, this dose produced an Irinotecan C<span class="Sub">max</span> and AUC about 2/3 and 1/40th, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span>. In rabbits, the teratogenic dose was about one-half the recommended human weekly starting dose on a mg/m<span class="Sup">2</span> basis. Teratogenic effects included a variety of external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring. There are no adequate and well-controlled studies of Irinotecan in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Irinotecan.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID842"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="ID843"></a>Radioactivity appeared in rat milk within 5 minutes of intravenous administration of radiolabeled Irinotecan and was concentrated up to 65-fold at 4 hours after administration relative to plasma concentrations. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Irinotecan, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID844"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="ID845"></a>The effectiveness of Irinotecan in pediatric patients has not been established. Results from two open-label, single arm studies were evaluated. One hundred and seventy children with refractory <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> were enrolled in one phase 2 trial in which 50 mg/ m<span class="Sup">2</span> of Irinotecan was infused for 5 consecutive days every 3 weeks. Grade 3-4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was experienced by 54 (31.8%) patients. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was complicated by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in 15 (8.8%) patients. Grade 3-4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was observed in 35 (20.6%) patients. This adverse event profile was comparable to that observed in adults. In the second phase 2 trial of 21 children with previously untreated <span class="product-label-link" type="condition" conceptid="4116201" conceptname="Rhabdomyosarcoma">rhabdomyosarcoma</span>, 20 mg/m<span class="Sup">2</span> of Irinotecan was infused for 5 consecutive days on weeks 0, 1, 3 and 4. This single agent therapy was followed by multimodal therapy. Accrual to the single agent Irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (14%). The adverse event profile was different in this study from that observed in adults; the most significant grade 3 or 4 adverse events were <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> experienced by 6 patients (28.6%) associated with severe <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in 5 patients (23.8%) and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in 3 patients (14.3%); in addition Grade 3-4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was reported in 5 patients (23.8%) (across all courses of therapy and irrespective of causal relationship). </p>
<p>Pharmacokinetic parameters for Irinotecan and SN-38 were determined in 2 pediatric solid-tumor trials at dose levels of 50 mg/m<span class="Sup">2</span> (60-min infusion, n=48) and 125 mg/m<span class="Sup">2</span> (90-min infusion, n=6). Irinotecan clearance (mean <span class="Underline">+</span> S.D.) was 17.3 <span class="Underline">+</span> 6.7 L/h/m<span class="Sup">2</span> for the 50mg/m<span class="Sup">2</span> dose and 16.2 <span class="Underline">+</span> 4.6 L/h/m<span class="Sup">2</span> for the 125 mg/m<span class="Sup">2</span> dose, which is comparable to that in adults. Dose-normalized SN-38 AUC values were comparable between adults and children. Minimal accumulation of Irinotecan and SN-38 was observed in children on daily dosing regimens [daily x 5 every 3 weeks or (daily x 5) x 2 weeks every 3 weeks]</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID846"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="ID847"></a>Patients greater than 65 years of age should be closely monitored because of a greater risk of early and late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in this population <span class="Italics">[see</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)</span> and <span class="Italics">Adverse</span>Â <span class="Italics">Reactions</span>Â <span class="Italics">(<a href="#ID808">6.1</a>)]</span>. The starting dose of Irinotecan in patients 70 years and older for the once-every-3-week-dosage schedule should be 300 mg/m<span class="Sup">2</span>Â <span class="Italics">[see</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p>The frequency of grade 3 and 4 late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> by age was significantly greater in patients â‰¥65 years than in patients &lt;65 years (40% [53/133] versus 23% [40/171]; p=0.002). In another study of 183 patients treated on the weekly schedule, the frequency of grade 3 or 4 late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in patients <span class="Underline">&gt;</span>65 years of age was 28.6% [26/91] and in patients &lt;65 years of age was 23.9% [22/92].</p>
</div>
<div class="Section">
<a name="ID848"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="ID849"></a>The influence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Irinotecan has not been evaluated. Therefore, use caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Irinotecan is not recommended for use in patients on dialysis.</p>
</div>
<div class="Section">
<a name="ID850"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="ID851"></a>Irinotecan clearance is diminished in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. Therefore, use caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The tolerability of Irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID753">2.1</a>)</span>, <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID803">5.10</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID852"></a><a name="section-9"></a><p></p>
<h1>10. OVERDOSAGE</h1>
<p class="First"><a name="ID853"></a>In U.S. phase 1 trials, single doses of up to 345 mg/m<span class="Sup">2</span> of Irinotecan were administered to patients with various cancers. Single doses of up to 750 mg/m<span class="Sup">2</span> of Irinotecan have been given in non-U.S. trials. The adverse events in these patients were similar to those reported with the recommended dosage and regimen. There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. There is no known antidote for overdosage of Irinotecan. Maximum supportive care should be instituted to prevent <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> due to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and to treat any infectious complications.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID854"></a><a name="section-10"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First"><a name="ID855"></a>Irinotecan hydrochloride Injection (Irinotecan hydrochloride injection) is an antineoplastic agent of the topoisomerase I inhibitor class. </p>
<p>Irinotecan is supplied as a sterile, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, clear, aqueous solution. Each milliliter of solution contains 20 mg of Irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol, NF, and 0.9 mg of lactic acid, USP. The pH of the solution has been adjusted to 3.5 (range, 3.2 to 3.8) with sodium hydroxide or hydrochloric acid. Irinotecan is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP. </p>
<p>Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as <span class="Italics">Camptotheca</span>Â <span class="Italics">acuminata</span> or is chemically synthesized<span class="Italics">.</span>Â </p>
<p>The chemical name is <span class="Italics">(<span class="Bold">S</span>)</span>-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1<span class="Bold"><span class="Italics">H</span></span>pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate. Its empirical formula is C<span class="Sub">33</span>H<span class="Sub">38</span>N<span class="Sub">4</span>O<span class="Sub">6</span>â€¢HClâ€¢3H<span class="Sub">2</span>O and molecular weight is 677.19. It is slightly soluble in water and organic solvents. Its structural formula is as follows:</p>
<div class="Figure"><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-14.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID857"></a><a name="section-11"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID858"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="ID859"></a>Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I, which relieves torsional <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase IDNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID860"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><a name="ID861"></a>Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from Irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as Irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. <span class="Italics">In</span>Â <span class="Italics">vitro</span> cytotoxicity assays show that the potency of SN-38 relative to Irinotecan varies from 2- to 2000-fold; however, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of Irinotecan and SN38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for Irinotecan <span class="Italics">[see</span>Â <span class="Italics">Clinical</span>Â <span class="Italics">Pharmacology</span>Â <span class="Italics">(<a href="#ID862">12.3</a>)]</span>. The precise contribution of SN38 to the activity of Irinotecan is thus unknown. Both Irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form. </p>
<p>Administration of Irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID862"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="ID863"></a>After intravenous infusion of Irinotecan in humans, Irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of Irinotecan and SN-38 are similar to those of total Irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium. </p>
<p>Over the recommended dose range of 50 to 350 mg/m<span class="Sup">2</span>, the AUC of Irinotecan increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within 1 hour following the end of a 90-minute infusion of Irinotecan. Pharmacokinetic parameters for Irinotecan and SN-38 following a 90-minute infusion of Irinotecan at dose levels of 125 and 340 mg/m<span class="Sup">2</span> determined in two clinical studies in patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> are summarized in Table 9:</p>
<div class="Figure"><img alt="Image 15" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-15.jpg"></div>
<p><a name="ID865"></a><span class="Bold"><span class="Italics">Distribution</span></span>Â </p>
<p>Irinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which Irinotecan and SN-38 predominantly binds is albumin. </p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span>Â </p>
<p>The metabolic conversion of Irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver<span class="Italics">.</span>Â <span class="Italics">In</span>Â <span class="Italics">vitro</span> studies indicate that Irinotecan, SN-38 and another metabolite aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1<span class="Sup">*</span>28 polymorphism. Approximately 10% of the North American population is homozygous for the UGT1A1<span class="Sup">*</span>28 allele (also referred to as UGT1A1 7/7 genotype). In a prospective study, in which Irinotecan was administered as a single-agent (350 mg/m<span class="Sup">2</span>) on a once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had a higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) <span class="Italics">[see</span>Â <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID789">5.3</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines <span class="Italics">in</span>Â <span class="Italics">vitro</span>.</p>
<p><span class="Bold"><span class="Italics">Excretion</span></span>Â </p>
<p>The disposition of Irinotecan has not been fully elucidated in humans. The urinary excretion of Irinotecan is 11% to 20%; SN-38, &lt;1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of Irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of Irinotecan in two patients ranged from approximately 25% (100 mg/m<span class="Sup">2</span>) to 50% (300 mg/m<span class="Sup">2</span>).</p>
<p><span class="Bold"><span class="Italics">Effect</span></span>Â <span class="Bold"><span class="Italics">of</span></span>Â <span class="Bold"><span class="Italics">Age</span></span>Â </p>
<p>The pharmacokinetics of Irinotecan administered using the weekly schedule was evaluated in a study of 183 patients that was prospectively designed to investigate the effect of age on Irinotecan toxicity. Results from this trial indicate that there are no differences in the pharmacokinetics of Irinotecan, SN-38, and SN-38 glucuronide in patients &lt;65 years of age compared with patients <span class="Underline">+</span> 65 years of age. In a study of 162 patients that was not prospectively designed to investigate the effect of age, small (less than 18%) but statistically significant differences in dose-normalized Irinotecan pharmacokinetic parameters in patients &lt;65 years of age compared to patients <span class="Underline">+</span> 65 years of age were observed. Although dose-normalized AUC0-24 for SN-38 in patients <span class="Underline">+</span> 65 years of age was 11% higher than in patients &lt;65 years of age, this difference was not statistically significant. No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of Irinotecan <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. </p>
<p><span class="Bold"><span class="Italics">Effect</span></span>Â <span class="Bold"><span class="Italics">of</span></span>Â <span class="Bold"><span class="Italics">Gender</span></span>Â </p>
<p>The pharmacokinetics of Irinotecan do not appear to be influenced by gender. </p>
<p><span class="Bold"><span class="Italics">Effect</span></span>Â <span class="Bold"><span class="Italics">of</span></span>Â <span class="Bold"><span class="Italics">Race</span></span>Â </p>
<p>The influence of race on the pharmacokinetics of Irinotecan has not been evaluated.</p>
<p><span class="Bold"><span class="Italics">Effect</span></span>Â <span class="Bold"><span class="Italics">of</span></span>Â <span class="Bold"><span class="Italics">Hepatic</span></span>Â <span class="Bold"><span class="Italics">Impairment</span></span>Â </p>
<p>Irinotecan clearance is diminished in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. However, the tolerability of Irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID753">2.1</a>)</span>, <span class="Italics">Warnings</span>Â <span class="Italics">and</span>Â <span class="Italics">Precautions</span>Â <span class="Italics">(<a href="#ID803">5.10</a>)</span>Â <span class="Italics">and</span>Â <span class="Italics">Use</span>Â <span class="Italics">in</span>Â <span class="Italics">Specific</span>Â <span class="Italics">Populations</span>Â <span class="Italics">(<a href="#ID850">8.7</a>)]</span>. </p>
<p><span class="Bold"><span class="Italics">Effect</span></span>Â <span class="Bold"><span class="Italics">of</span></span>Â <span class="Bold"><span class="Italics">Renal</span></span>Â <span class="Bold"><span class="Italics">Impairment</span></span>Â </p>
<p>The influence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of Irinotecan has not been evaluated. Therefore, caution should be undertaken in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Irinotecan is not recommended for use in patients on dialysis <span class="Italics">[see</span>Â <span class="Italics">Use</span>Â <span class="Italics">in</span>Â <span class="Italics">Specific</span>Â <span class="Italics">Populations</span>Â <span class="Italics">(<a href="#ID848">8.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID866"></a><a name="section-12"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY</h1>
<div class="Section">
<a name="ID867"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID868"></a>Long-term carcinogenicity studies with Irinotecan were not conducted. Rats were, however, administered intravenous doses of 2 mg/kg or 25 mg/kg Irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an Irinotecan C<span class="Sub">max</span> and AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m<span class="Sup">2</span> weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was a significant linear trend with dose for the incidence of combined uterine horn endometrial stromal <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and endometrial stromal <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>. Irinotecan was clastogenic both <span class="Italics">in</span>Â <span class="Italics">vitro</span> (chromosome aberrations in Chinese hamster ovary cells) and <span class="Italics">in</span>Â <span class="Italics">vivo</span> (micronucleus test in mice). Neither Irinotecan nor its active metabolite SN-38 was mutagenic in the <span class="Italics">in</span>Â <span class="Italics">vitro</span> Ames assay. </p>
<p>No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of Irinotecan in doses of up to 6 mg/kg/day to rats and rabbits; however, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of male reproductive organs was observed after multiple daily Irinotecan doses both in rodents at 20 mg/kg and in dogs at 0.4 mg/kg. In separate studies in rodents, this dose produced an Irinotecan C<span class="Sub">max</span> and AUC about 5 and 1 times, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span> weekly. In dogs this dose produced an Irinotecan C<span class="Sub">max</span> and AUC about one-half and 1/15th, respectively, of the corresponding values in patients administered 125 mg/m<span class="Sup">2</span> weekly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID869"></a><a name="section-13"></a><p></p>
<h1>14. CLINICAL STUDIES</h1>
<p class="First"><a name="ID870"></a>Irinotecan has been studied in clinical trials in combination with 5-fluorouracil (5-FU) and leucovorin (LV) and as a single agent <span class="Italics">[see</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">and</span>Â <span class="Italics">Administration</span>Â <span class="Italics">(<a href="#ID750">2</a>)]</span>. When given as a component of combination-agent treatment, Irinotecan was either given with a weekly schedule of bolus 5-FU/LV or with an every-2-week schedule of infusional 5-FU/LV. Weekly and once-every-3-week dosage schedules were used for the single-agent Irinotecan studies. Clinical studies of combination and single-agent use are described below.</p>
<div class="Section">
<a name="ID871"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Metastatic Colorectal Cancer</h2>
<p class="First"><a name="ID872"></a><span class="Italics">First</span>Â <span class="Italics">Line</span>Â <span class="Italics">Therapy</span>Â <span class="Italics">in</span>Â <span class="Italics">Combination</span>Â <span class="Italics">with</span>Â <span class="Italics">5-FU/LV:</span>Â <span class="Italics">Studies</span>Â <span class="Italics">1</span>Â <span class="Italics">and</span>Â <span class="Italics">2</span>Â </p>
<p>Two phase 3, randomized, controlled, multinational clinical trials support the use of Irinotecan hydrochloride Injection as first-line treatment of patients with metastatic carcinoma of the colon or rectum. In each study, combinations of Irinotecan with 5-FU and LV were compared with 5FU and LV alone. Study 1 compared combination Irinotecan/bolus 5-FU/LV therapy given weekly with a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks; an Irinotecan-alone treatment arm given on a weekly schedule was also included. Study 2 evaluated two different methods of administering infusional 5-FU/LV, with or without Irinotecan. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. In Study 2, a 7-day course of fluoroquinolone antibiotic prophylaxis was given in patients whose <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> persisted for greater than 24 hours despite loperamide or if they developed a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> in addition to <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Treatment with oral fluoroquinolone was also initiated in patients who developed an absolute neutrophil count (ANC) &lt;500/mm<span class="Sup">3</span>, even in the absence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Patients in both studies also received treatment with intravenous antibiotics if they had persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or if <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> developed. </p>
<p>In both studies, the combination of Irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor response rates, time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>, and survival when compared with 5-FU/LV alone. These differences in survival were observed in spite of second-line therapy in a majority of patients on both arms, including crossover to Irinotecan-containing regimens in the control arm. Patient characteristics and major efficacy results are shown in Table </p>
<p>10. </p>
<div class="Figure"><img alt="Image 16" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-16.jpg"></div>
<p><a name="ID874"></a>Improvement was noted with Irinotecan-based combination therapy relative to 5-FU/LV when response rates and time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> were examined across the following demographic and disease-related subgroups (age, gender, ethnic origin, performance status, extent of organ involvement with cancer, time from diagnosis of cancer, prior adjuvant therapy, and baseline laboratory abnormalities). Figures 1 and 2 illustrate the Kaplan-Meier survival curves for the comparison of Irinotecan/5-FU/LV versus 5-FU/LV in Studies 1 and 2, respectively.</p>
<div class="Figure"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-17.jpg"></div>
<div class="Figure"><img alt="Image 18" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-18.jpg"></div>
<p><a name="ID877"></a><span class="Italics"><span class="Underline">Second-Line</span></span><span class="Underline">Â <span class="Italics">Therapy</span>Â <span class="Italics">After</span>Â <span class="Italics">5-FU-Based</span>Â <span class="Italics">Treatment</span>Â </span></p>
<p><span class="Italics">4</span>Â <span class="Italics">Weekly</span>Â <span class="Italics">Doses</span>Â <span class="Italics">on</span>Â <span class="Italics">a</span>Â <span class="Italics">6-Week</span>Â <span class="Italics">Cycle:</span>Â <span class="Italics">Studies</span>Â <span class="Italics">3</span>, <span class="Italics">4</span>, <span class="Italics">and</span>Â <span class="Italics">5</span>Â </p>
<p>Data from three open-label, single-agent, clinical studies, involving a total of 304 patients in 59 centers, support the use of Irinotecan in the treatment of patients with metastatic cancer of the colon or rectum that has recurred or progressed following treatment with 5-FU-based therapy. These studies were designed to evaluate tumor response rate and do not provide information on effects on survival and disease-related symptoms. In each study, Irinotecan was administered in repeated 6-week cycles consisting of a 90-minute intravenous infusion once weekly for 4 weeks, followed by a 2-week rest period. Starting doses of Irinotecan in these trials were 100, 125, or 150 mg/m<span class="Sup">2</span>, but the 150-mg/m<span class="Sup">2</span> dose was poorly tolerated (due to high rates of grade 4 late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>). Study 3 enrolled 48 patients and was conducted by a single investigator at several regional hospitals. Study 4 was a multicenter study conducted by the North Central Cancer Treatment Group. All 90 patients enrolled in Study 4 received a starting dose of 125 mg/m<span class="Sup">2</span>. Study 5 was a multicenter study that enrolled 166 patients from 30 institutions. The initial dose in Study 5 was 125 mg/m<span class="Sup">2</span> but was reduced to 100 mg/m<span class="Sup">2</span> because the toxicity seen at the 125-mg/m<span class="Sup">2</span> dose was perceived to be greater than that seen in previous studies. All patients in these studies had metastatic colorectal cancer, and the majority had disease that recurred or progressed following a 5-FU-based regimen administered for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. The results of the individual studies are shown in Table 11.</p>
<div class="Figure"><img alt="Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-19.jpg"></div>
<div class="Figure"><img alt="Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-20.jpg"></div>
<p><a name="ID880"></a>In the intent-to-treat analysis of the pooled data across all three studies, 193 of the 304 patients began therapy at the recommended starting dose of 125 mg/m<span class="Sup">2</span>. Among these 193 patients, 2 complete and 27 partial responses were observed, for an overall response rate of 15.0% (95% Confidence Interval [CI], 10.0% to 20.1%) at this starting dose. A considerably lower response rate was seen with a starting dose of 100 mg/m<span class="Sup">2</span>. The majority of responses were observed within the first two cycles of therapy, but responses did occur in later cycles of treatment (one response was observed after the eighth cycle). The median response duration for patients beginning therapy at 125 mg/m<span class="Sup">2</span> was 5.8 months (range, 2.6 to 15.1 months). Of the 304 patients treated in the three studies, response rates to Irinotecan were similar in males and females and among patients older and younger than 65 years. Rates were also similar in patients with cancer of the colon or cancer of the rectum and in patients with single and multiple metastatic sites. The response rate was 18.5% in patients with a performance status of 0 and 8.2% in patients with a performance status of 1 or 2. Patients with a performance status of 3 or 4 have not been studied. Over half of the patients responding to Irinotecan had not responded to prior 5-FU. Patients who had received previous irradiation to the pelvis responded to Irinotecan at approximately the same rate as those who had not previously received irradiation. </p>
<p><span class="Italics">Once-Every-3-Week</span>Â <span class="Italics">Dosage</span>Â <span class="Italics">Schedule</span>Â </p>
<p><span class="Italics">Single</span>Â <span class="Italics">Arm</span>Â <span class="Italics">Study:</span>Â <span class="Italics">Study</span>Â <span class="Italics">6</span>Â </p>
<p>Data from an open-label, single-agent, single-arm, multicenter, clinical study involving a total of 132 patients support a once every-3-week dosage schedule of Irinotecan in the treatment of patients with metastatic cancer of the colon or rectum that recurred or progressed following treatment with 5-FU. Patients received a starting dose of 350 mg/m<span class="Sup">2</span> given by 30-minute intravenous infusion once every 3 weeks. Among the 132 previously treated patients in this trial, the intent-to-treat response rate was 12.1% (95% CI, 7.0% to 18.1%). </p>
<p><span class="Italics">Randomized</span>Â <span class="Italics">Studies:</span>Â <span class="Italics">Studies</span>Â <span class="Italics">7</span>Â <span class="Italics">and</span>Â <span class="Italics">8</span>Â </p>
<p>Two multicenter, randomized, clinical studies further support the use of Irinotecan given by the once-every-3-week dosage schedule in patients with metastatic colorectal cancer whose disease has recurred or progressed following prior 5-FU therapy. In Study 7, second-line Irinotecan therapy plus best supportive care was compared with best supportive care alone. In Study 8, second-line Irinotecan therapy was compared with infusional 5-FU-based therapy. In both studies, Irinotecan was administered intravenously at a starting dose of 350 mg/m<span class="Sup">2</span> over 90 minutes once every 3 weeks. The starting dose was 300 mg/m<span class="Sup">2</span> for patients who were 70 years and older or who had a performance status of 2. The highest total dose permitted was 700 mg. Dose reductions and/or administration delays were permitted in the event of severe hematologic and/or nonhematologic toxicities while on treatment. Best supportive care was provided to patients in both arms of Study 7 and included antibiotics, analgesics, corticosteroids, transfusions, psychotherapy, or any other symptomatic therapy as clinically indicated. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. If late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> persisted for greater than 24 hours despite loperamide, a 7-day course of fluoroquinolone antibiotic prophylaxis was given. Patients in the control arm of the Study 8 received one of the following 5-FU regimens: (1) LV, 200 mg/m<span class="Sup">2</span> IV over 2 hours; followed by 5-FU, 400 mg/m<span class="Sup">2</span> IV bolus; followed by 5-FU, 600 mg/m<span class="Sup">2</span> continuous IV infusion over 22 hours on days 1 and 2 every 2 weeks; (2) 5-FU, 250 to 300 mg/m<span class="Sup">2</span>/day protracted continuous IV infusion until toxicity; (3) 5FU, 2.6 to 3 g/m<span class="Sup">2</span> IV over 24 hours every week for 6 weeks with or without LV, 20 to 500 mg/m<span class="Sup">2</span>/day every week IV for 6 weeks with 2-week rest between cycles. Patients were to be followed every 3 to 6 weeks for 1 year. </p>
<p>A total of 535 patients were randomized in the two studies at 94 centers. The primary endpoint in both studies was survival. The studies demonstrated a significant overall survival advantage for Irinotecan compared with best supportive care (p=0.0001) and infusional 5-FU-based therapy (p=0.035) as shown in Figures 3 and 4. In Study 7, median survival for patients treated with Irinotecan was 9.2 months compared with 6.5 months for patients receiving best supportive care. In Study 8, median survival for patients treated with Irinotecan was 10.8 months compared withÂ  8.5 months for patients receiving infusional 5-FU-based therapy. Multiple regression analyses determined that patients' baseline characteristics also had a significant effect on survival. When adjusted for performance status and other baseline prognostic factors, survival among patients treated with Irinotecan remained significantly longer than in the control populations (p=0.001 for Study 7 and p=0.017 for Study 8). Measurements of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, performance status, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> were collected prospectively in the two studies; however, the plan for the analysis of these data was defined retrospectively. When comparing Irinotecan with best supportive care in Study 7, this analysis showed a statistically significant advantage for Irinotecan, with longer time to development of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (6.9 months versus 2.0 months), time to performance status deteriorationÂ  (5.7 months versus 3.3 months), and time to &gt; 5% <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> (6.4 months versus 4.2 months). Additionally, 33.3% (33/99) of patients with a baseline performance status of 1 or 2 showed an improvement in performance status when treated with Irinotecan versus 11.3% (7/62) of patients receiving best supportive care (p=0.002). Because of the inclusion of patients with non-measurable disease, intent-to-treat response rates could not be assessed.</p>
<div class="Figure"><img alt="Image 21" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-21.jpg"></div>
<div class="Figure"><img alt="Image 22" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-22.jpg"></div>
<div class="Figure"><img alt="Image 23" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-23.jpg"></div>
<p><a name="ID884"></a>In the two randomized studies, the EORTC QLQ-C30 instrument was utilized. At the start of each cycle of therapy, patients completed a questionnaire consisting of 30 questions, such as "Did <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> interfere with daily activities?" (1 = Not at All, to 4 = Very Much) and "Do you have any trouble taking a long walk?" (Yes or No). The answers from the 30 questions were converted into 15 subscales, that were scored from 0 to 100, and the global health status subscale that was derived from two questions about the patient's sense of general well being in the past week. The results as summarized in Table 13 are based on patients' worst post-baseline scores. In Study 7, a multivariate analysis and univariate analyses of the individual subscales were performed and corrected for multivariate testing. Patients receiving Irinotecan reported significantly better results for the global health status, on two of five functional subscales, and on four of nine symptom subscales. As expected, patients receiving Irinotecan noted significantly more <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> than those receiving best supportive care. In Study 8, the multivariate analysis on all 15 subscales did not indicate a statistically significant difference between Irinotecan and infusional 5-FU.</p>
<p><a name="ID897"></a>In the two randomized studies, the EORTC QLQ-C30 instrument was utilized. At the start of each cycle of therapy, patients completed a questionnaire consisting of 30 questions, such as "Did <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> interfere with daily activities?" (1 = Not at All, to 4 = Very Much) and "Do you have any trouble taking a long walk?" (Yes or No). The answers from the 30 questions were converted into 15 subscales, that were scored from 0 to 100, and the global health status subscale that was derived from two questions about the patient's sense of general well being in the past week. The results as summarized in Table 13 are based on patients' worst post-baseline scores. In Study 7, a multivariate analysis and univariate analyses of the individual subscales were performed and corrected for multivariate testing. Patients receiving Irinotecan reported significantly better results for the global health status, on two of five functional subscales, and on four of nine symptom subscales. As expected, patients receiving Irinotecan noted significantly more <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> than those receiving best supportive care. In Study 8, the multivariate analysis on all 15 subscales did not indicate a statistically significant difference between Irinotecan and infusional 5-FU.</p>
<div class="Figure"><img alt="Image 24" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-24.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID886"></a><a name="section-14"></a><p></p>
<h1>15. REFERENCES</h1>
<ul class="Disc">
<li>Â  NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. </li>
<li>Â  OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. <span class="Underline">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html </span>Â </li>
<li>Â  American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am</span>Â <span class="Italics">J</span>Â <span class="Italics">Health-Syst</span>Â <span class="Italics">Pharm.</span>  2006; 63:1172-1193. </li>
<li>Â  Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID888"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="ID889"></a>Irinotecan hydrochloride Injection is available in single-dose amber glass vials in the following package sizes: </p>
<p>2 mL NDC 53104 0151 2 </p>
<p>5 mL NDC 53104 0151 3</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP controlled room temperature.]. Protect from light. Keep the vial in the carton until the time of use. </p>
<p>Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID890"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION</h1>
<ul class="Disc">
<li>Â  Patients and caregivers should be informed of gastrointestinal complications, such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, abdominal cramping, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Patients should have loperamide readily available to begin treatment for late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (generally occurring more than 24 hours after administration of Irinotecan). Begin loperamide at the first episode of poorly formed or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> or the earliest onset of bowel movements more frequent than normal. One dosage regimen for loperamide is 4 mg at the first onset of late <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and then 2 mg every 2 hours until the patient is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. During the night, the patient may take 4 mg of loperamide every 4 hours. Patients should contact their physician if any of the following occur: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> for the first time during treatment; black or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>; symptoms of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or faintness; inability to take fluids by mouth due to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; or inability to get <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> under control within 24 hours. </li>
<li>Â  Patients should be warned about the potential for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> which may occur within 24 hours following the administration of Irinotecan. </li>
<li>Â  Explain the significance of routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </li>
<li>Â  Irinotecan may cause fetal harm. Advice patients to avoid becoming pregnant while receiving this drug. </li>
<li>Â  Patients should be alerted to the possibility of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>. </li>
<li>Â  Contains sorbitol. </li>
</ul>
<p class="First"><a name="ID892"></a><span class="Bold">Manufactured</span>Â <span class="Bold">by:</span></p>
<p>Cipla Ltd.</p>
<p>Verna Goa, INDIA</p>
<p><span class="Bold">Issued: February 2013</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID899"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><a name="ID900"></a><span class="Bold">Vial label for Irinotecan Hydrochloride Injection 40mg/2ml</span></p>
<p><span class="Bold">Rx only  NDC 53104-0151-2</span></p>
<p><span class="Bold">IRINOTECAN HYDROCHLORIDE INJECTION </span></p>
<p><span class="Bold">40mg/2ml</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY â€“ </span>must be diluted before use.</p>
<p><span class="Bold">CAUTION: Cytotoxic agent</span></p>
<p><span class="Bold">2ml Single â€“Use Vial</span></p>
<p><span class="Bold">Cipla</span></p>
<div class="Figure"><img alt="Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-25.jpg"></div>
<p><a name="ID902"></a><span class="Bold">Vial label for Irinotecan Hydrochloride Injection 100mg/5ml</span></p>
<p><span class="Bold">Rx only  NDC 53104-0151-3</span></p>
<p><span class="Bold">IRINOTECAN HYDROCHLORIDE INJECTION </span></p>
<p><span class="Bold">100mg/5ml</span></p>
<p><span class="Bold">FOR INTRAVENOUS USE ONLY â€“ </span>must be diluted before use.</p>
<p><span class="Bold">CAUTION: Cytotoxic agent</span></p>
<p><span class="Bold">5ml Single â€“Use Vial</span></p>
<p><span class="Bold">Cipla</span></p>
<div class="Figure"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=407e0758-9e2e-4e45-8c1b-10cfd2115b1f&amp;name=iri03-0000-26.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IRINOTECAN HYDROCHLORIDEÂ 		
					</strong><br><span class="contentTableReg">irinotecan hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53104-0151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IRINOTECAN HYDROCHLORIDE</strong> (IRINOTECAN) </td>
<td class="formItem">IRINOTECAN HYDROCHLORIDE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW ((A clear, colorless to plae yellow solution)) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53104-0151-2</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:53104-0151-3</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077219</td>
<td class="formItem">02/20/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cipla Limited
							(650138746)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Cipla Limited (650138746)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cipla Ltd.- Goa</td>
<td class="formItem"></td>
<td class="formItem">650072015</td>
<td class="formItem">Manufacture(53104-0151)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>851894a7-97eb-4d90-b7e8-0fb950bc0dc2</div>
<div>Set id: 407e0758-9e2e-4e45-8c1b-10cfd2115b1f</div>
<div>Version: 2</div>
<div>Effective Time: 20130204</div>
</div>
</div>Â <div class="DistributorName">Cipla Limited</div></p>
</body></html>
